Related Experiment Video
Updated: Aug 7, 2026

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Published on: July 3, 2025
Anastrozole for breast cancer: recent advances and ongoing challenges
1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1354, Houston, TX 77030-4009, USA. abuzdar@mdanderson.org
Abstract:
Third-generation aromatase inhibitors are accepted widely as alternatives to tamoxifen for the treatment of advanced breast cancer in postmenopausal women and, currently, are increasingly replacing tamoxifen in the adjuvant setting. This drug profile focuses on recent clinical developments in the use of anastrozole and, in particular, on the Arimidex, Tamoxifen, Alone or in Combination trial, which has shown that initial adjuvant treatment with anastrozole has significant efficacy and tolerability advantages compared with tamoxifen for postmenopausal women with early breast cancer. Results of adjuvant switching, extended adjuvant and preoperative (neoadjuvant) studies are reviewed and the potential of anastrozole in a range of clinical settings is discussed. Treatment recommendations and the future role of anastrozole in the management of patients with early breast cancer are also considered.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer Survival Analysis
